COMUNICATO STAMPA - CONTENUTO PROMOZIONALE
BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results.
Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year increase. This included around RMB 310 million from sales of the core product Kangyueda® and
As of the date of this announcement, the new drug applications of Kangyueda® for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyps (CRSwNP) and seasonal allergic rhinitis (SAR) have been approved by the NMPA. Since January 2026, all launched indications have been included in the National Reimbursement Drug List of China, significantly enhancing affordability and accessibility for Chinese patients. During the Reporting Period, revenue for sales of Kangyueda® amounted to approximately RMB315 million.
The company has established a diverse set of technology platforms, including Antibodies Discovery Platform, ADC Platform, TCE Bispecific Antibodies Platform, Oligonucleotide Platform, Small Molecule Platform and Blood-Brain Barrier-Penetrating Antibody Delivery Platform. Leveraging synergistic platform innovation capabilities, the company continues to generate high-quality innovative medicines to patients around the world.
More information: https://en.keymedbio.com/en/index.html
View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-2025-annual-results-and-business-updates-302726287.html
Copyright 2026 PR Newswire. All Rights Reserved.
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE: Immediapress è un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall'ente che lo emette. L'Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi
